Other forms of sporotrichosis
ICD-10 B41.8 is a billable code used to indicate a diagnosis of other forms of sporotrichosis.
Sporotrichosis is a fungal infection caused by the dimorphic fungus Sporothrix schenckii, which is commonly found in soil, plants, and decaying organic matter. The infection typically manifests as cutaneous lesions, but can also disseminate to other systems, particularly in immunocompromised individuals. Other forms of sporotrichosis may include lymphocutaneous sporotrichosis, which is characterized by nodular lesions along lymphatic pathways, and disseminated sporotrichosis, which can affect multiple organs. The clinical presentation can vary significantly based on the host's immune status, with more severe manifestations occurring in those who are immunocompromised, such as patients with HIV/AIDS, those on immunosuppressive therapy, or individuals with underlying malignancies. Diagnosis is primarily through clinical evaluation and culture of the organism from lesions or other affected tissues. Treatment typically involves antifungal therapy, with itraconazole being the first-line agent, although amphotericin B may be necessary for severe cases or disseminated disease. The management of sporotrichosis in immunocompromised patients requires careful monitoring and may necessitate prolonged antifungal therapy.
Detailed clinical history, lab results, and treatment plans must be documented.
Patients presenting with skin lesions, lymphadenopathy, or systemic symptoms.
Consideration of patient’s immune status and potential for co-infections.
Photographic evidence of lesions and detailed descriptions of skin findings.
Patients with chronic skin lesions or those with a history of exposure to soil or plants.
Differentiation from other dermatological conditions is crucial.
Used to confirm diagnosis of sporotrichosis.
Document the site of culture and results.
Infectious disease specialists may require additional lab tests.
Sporotrichosis is a fungal infection caused by Sporothrix schenckii, often presenting as skin lesions and can disseminate in immunocompromised patients.
Treatment typically involves antifungal medications such as itraconazole, with more severe cases requiring amphotericin B.
Risk factors include immunocompromised status, exposure to soil or plants, and certain occupational hazards.
